Fresenius Medical Care Forecast, price target & analysts
Fresenius Medical Care Target price 2025 - Analyst rating & recommendation
Fresenius Medical Care Classifications & Recommendation:
Fresenius Medical Care Price Target
| Target Price | €47.86 |
| Price | €41.58 |
| Potential | 15.11% |
| Number of Estimates | 20 |
| 20 Analysts have issued a price target Fresenius Medical Care 2026 . The average Fresenius Medical Care target price is €47.86. This is 15.11% higher than the current stock price. The highest price target is €57.50 38.29% , the lowest is €37.00 11.01% . | |
| A rating was issued by 23 analysts: 8 Analysts recommend Fresenius Medical Care to buy, 10 to hold and 5 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Fresenius Medical Care stock has an average upside potential 2026 of 15.11% . Most analysts recommend the Fresenius Medical Care stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2029
19 Analysts have issued a sales forecast Fresenius Medical Care 2025 . The average Fresenius Medical Care sales estimate is €19.9b . This is 3.07% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €20.6b 6.73% , the lowest is €19.2b 0.83% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | €19.3b | 0.60% |
|---|---|---|
| 2025 | €19.9b | 3.06% |
| 2026 | €20.6b | 3.55% |
| 2027 | €21.4b | 3.62% |
| 2028 | €22.3b | 4.31% |
| 2029 | €23.9b | 7.11% |
16 Analysts have issued an Fresenius Medical Care EBITDA forecast 2025. The average Fresenius Medical Care EBITDA estimate is €3.8b . This is 15.87% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €3.9b 19.00% , the lowest is €3.6b 10.93% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | €3.2b | 0.64% |
|---|---|---|
| 2025 | €3.8b | 18.72% |
| 2026 | €3.9b | 3.74% |
| 2027 | €4.2b | 6.12% |
| 2028 | €4.0b | 3.84% |
| 2029 | €3.2b | 19.94% |
EBITDA Margin
| 2024 | 16.44% | 0.04% |
|---|---|---|
| 2025 | 18.94% | 15.19% |
| 2026 | 18.98% | 0.21% |
| 2027 | 19.43% | 2.37% |
| 2028 | 17.91% | 7.82% |
| 2029 | 13.39% | 25.24% |
14 Fresenius Medical Care Analysts have issued a net profit forecast 2025. The average Fresenius Medical Care net profit estimate is €988m . This is 84.01% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €1.2b 116.39% , the lowest is €883m 64.48% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | €537m | 7.65% |
|---|---|---|
| 2025 | €988m | 84.01% |
| 2026 | €1.2b | 18.00% |
| 2027 | €1.3b | 11.85% |
| 2028 | €1.4b | 10.48% |
| 2029 | €1.5b | 7.43% |
Net Margin
| 2024 | 2.78% | 8.29% |
|---|---|---|
| 2025 | 4.96% | 78.63% |
| 2026 | 5.65% | 13.91% |
| 2027 | 6.10% | 7.96% |
| 2028 | 6.46% | 5.90% |
| 2029 | 6.48% | 0.31% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
14 Analysts have issued a Fresenius Medical Care forecast for earnings per share. The average Fresenius Medical Care EPS is €3.37 . This is 84.15% higher than earnings per share in the financial year 2024. The highest EPS forecast is €3.96 116.39% , the lowest is €3.01 64.48% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | €1.83 | 7.65% |
|---|---|---|
| 2025 | €3.37 | 84.15% |
| 2026 | €3.97 | 17.80% |
| 2027 | €4.44 | 11.84% |
| 2028 | €4.91 | 10.59% |
| 2029 | €5.28 | 7.54% |
P/E ratio
| Current | 22.68 | 8.83% |
|---|---|---|
| 2025 | 12.35 | 45.55% |
| 2026 | 10.46 | 15.30% |
| 2027 | 9.36 | 10.52% |
| 2028 | 8.47 | 9.51% |
| 2029 | 7.88 | 6.97% |
Based on analysts' sales estimates for 2025, the Fresenius Medical Care stock is valued at an EV/Sales of 1.16 and an P/S ratio of 0.61 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.19 | 4.39% |
|---|---|---|
| 2025 | 1.16 | 2.85% |
| 2026 | 1.12 | 3.43% |
| 2027 | 1.08 | 3.49% |
| 2028 | 1.03 | 4.13% |
| 2029 | 0.96 | 6.64% |
P/S ratio
| Current | 0.63 | 18.04% |
|---|---|---|
| 2025 | 0.61 | 2.96% |
| 2026 | 0.59 | 3.43% |
| 2027 | 0.57 | 3.50% |
| 2028 | 0.55 | 4.12% |
| 2029 | 0.51 | 6.64% |
Fresenius Medical Care...
Current Fresenius Medical Care Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Buy
➜
Buy
|
Unchanged | Mar 31 2025 |
| HSBC |
Hold
➜
Buy
|
Upgrade | Mar 23 2025 |
| JEFFERIES |
Underperform
➜
Underperform
|
Unchanged | Mar 20 2025 |
| METZLER EQUITIES |
Buy
➜
Buy
|
Unchanged | Feb 27 2025 |
| WARBURG RESEARCH GMBH |
Sell
➜
Hold
|
Upgrade | Feb 26 2025 |
| LANDESBANK BADEN-WUERTTEMBERG |
Hold
➜
Hold
|
Unchanged | Feb 25 2025 |
| ODDO BHF |
Buy
➜
Buy
|
Unchanged | Feb 24 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Mar 31 2025 |
|
Upgrade
HSBC:
Hold
➜
Buy
|
Mar 23 2025 |
|
Unchanged
JEFFERIES:
Underperform
➜
Underperform
|
Mar 20 2025 |
|
Unchanged
METZLER EQUITIES:
Buy
➜
Buy
|
Feb 27 2025 |
|
Upgrade
WARBURG RESEARCH GMBH:
Sell
➜
Hold
|
Feb 26 2025 |
|
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Hold
➜
Hold
|
Feb 25 2025 |
|
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Feb 24 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
